Three experimental injectable antiretrovirals – a novel capsid inhibitor and two next-generation integrase inhibitors – could ...

Today, advancements in medicine have rendered HIV a manageable condition that allows most individuals to enjoy a typical ...

– Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the ...

A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in the lab.

A new single-pill HIV treatment has proved as effective as regimens of up to 11 tablets a day in suppressing the virus in hard-to-treat patients. It’s “a potential breakthrough for a growing cohort of ...

Over the next week, we'll be looking back at some of our favorite Goats and Soda stories to see "whatever happened to ..." In July 2024, we published a story with the headline: "One of the 7 people ...

For millions of people living with HIV, a daily regimen of medications is a lifelong necessity. If they stop taking the drugs—commonly referred to as antiretroviral therapy—the virus usually rushes ...

Modern HIV treatment is one of medicine's great success stories. With today's therapies, many people living with HIV can ...

Harerimana Ismail of Uganda is a community health worker who checks on kids with HIV. He lost his salary after the Trump ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented ...